| 3563 |
2330: SIX1 protein expression, increased |
1066: Promotion, SIX1 positive progenitor cells in endometrium |
Aug 5, 2025 |
Sep 18, 2025 |
1 AOP
|
| 2438 |
1904: six1b expression, increased |
1905: eya1 expression, inhibited |
Jul 14, 2021 |
Aug 13, 2021 |
1 AOP
|
| 3434 |
2291: Bradycardia |
2292: Altered Cardiac Electrical Conduction |
Nov 22, 2024 |
Nov 22, 2024 |
2 AOPs
|
| 1279 |
1222: SP (Substance P) release, Local increase of SP |
1224: Non-neuronal production of TNF, Epithelial irritation |
Nov 29, 2016 |
Nov 29, 2016 |
None
|
| 1574 |
1222: SP (Substance P) release, Local increase of SP |
1223: Increased Airway Hyper-responsiveness,Cough, Dyspnea |
Jun 23, 2017 |
Jun 23, 2017 |
None
|
| 1577 |
1222: SP (Substance P) release, Local increase of SP |
1225: Leukocyte infiltration |
Jun 23, 2017 |
Jun 23, 2017 |
None
|
| 1772 |
1222: SP (Substance P) release, Local increase of SP |
1226: Respiratory irritability |
Sep 24, 2018 |
Sep 24, 2018 |
1 AOP
|
| 1734 |
1515: Spermatocyte depletion |
1506: Testicular atrophy |
May 22, 2018 |
Jul 28, 2021 |
1 AOP
|
| 1024 |
1000: stabilization, PPAR alpha co-repressor |
858: Decreased, PPARalpha transactivation of gene expression |
Nov 29, 2016 |
Jun 11, 2018 |
1 AOP
|
| 2141 |
1788: Status epilepticus |
388: Overactivation, NMDARs |
May 21, 2020 |
May 21, 2020 |
None
|
| 2782 |
1788: Status epilepticus |
1350: Increased, glutamate |
Oct 12, 2022 |
Sep 3, 2023 |
1 AOP
|
| 2783 |
1788: Status epilepticus |
389: Increased, Intracellular Calcium overload |
Oct 12, 2022 |
Jul 24, 2023 |
1 AOP
|
| 2017 |
1706: Stimulation of TLR7/8 |
1707: Increase of IL-23 |
Dec 27, 2019 |
Dec 27, 2019 |
1 AOP
|
| 3207 |
2226: Binding PPAR isoforms |
2224: Dysregulation of transcriptional expression within PPAR signaling network |
May 8, 2024 |
May 8, 2024 |
None
|
| 3208 |
2226: Binding PPAR isoforms |
179: Decrease, Fatty acid β-oxidation |
May 8, 2024 |
May 8, 2024 |
None
|
| 3220 |
2226: Binding PPAR isoforms |
2227: Disrupted PPAR isoform nuclear signaling |
May 14, 2024 |
May 23, 2024 |
1 AOP
|
| 3399 |
2279: Structural changes in lamin A/C |
2066: Altered Signaling |
Nov 20, 2024 |
Nov 20, 2024 |
1 AOP
|
| 1968 |
1671: Substance - LS interaction |
1672: Inhibition of LS function. |
Jul 3, 2019 |
Jul 3, 2019 |
None
|
| 1702 |
1495: Interaction with the lung cell membrane |
1496: Increased proinflammatory mediators |
Jan 5, 2018 |
Feb 20, 2025 |
3 AOPs
|
| 2662 |
1495: Interaction with the lung cell membrane |
1115: Increase, ROS |
May 25, 2022 |
May 25, 2022 |
1 AOP
|
| 2663 |
1495: Interaction with the lung cell membrane |
1669: Increased, DNA damage and mutation |
May 25, 2022 |
May 25, 2022 |
1 AOP
|
| 2958 |
1495: Interaction with the lung cell membrane |
1438: Increased transcription of genes encoding acute phase proteins |
Jul 4, 2023 |
Jan 20, 2025 |
1 AOP
|
| 2959 |
1495: Interaction with the lung cell membrane |
1439: Systemic acute phase response |
Jul 4, 2023 |
Jan 20, 2025 |
1 AOP
|
| 2960 |
1495: Interaction with the lung cell membrane |
1443: Atherosclerosis |
Jul 4, 2023 |
Feb 19, 2025 |
1 AOP
|
| 3303 |
2243: Succinate Accumulation |
1619: Increase, DNMT inhibition |
Jul 18, 2024 |
Jul 18, 2024 |
1 AOP
|